Using cutoffs for MYC and BCL2 positivity of ≥40% and ≥70%, respectively (similar to cutoffs used in prior studies of systemic DLBCL [10], [21]), 43 (73%) cases were considered as overexpressing MYC and denoted MYC+, 41 (71%) were considered BCL2+, and 35 (60%) were considered MYC+ and BCL2+ (“double positive”). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.